Patents Represented by Attorney, Agent or Law Firm Incyte Pharmaceuticals, Inc.
-
Patent number: 6060297Abstract: The present invention provides a human Rho protein (HRHO) and polynucleotides which identify and encode HRHO. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing HRHO and for treating or preventing disorders associated with expression of HRHO.Type: GrantFiled: April 17, 1997Date of Patent: May 9, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 6060239Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode novel cellubrevins (cb). The present invention also provides for antisense molecules to the nucleotide sequences which encode cbs, expression vectors for the production of purified CBs, antibodies capable of binding specifically to CBs, hybridization probes or oligonucleotides for the detecting the induction of CB encoding nucleotide sequences, genetically engineered host cells for the expression of CBs, diagnostic tests for activated, inflamed or diseased cells and/or tissues based on CB-encoding nucleic acid molecules and antibodies capable of binding specifically to CBs.Type: GrantFiled: March 22, 1996Date of Patent: May 9, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Susan G. Stuart, Phillip R. Hawkins, Jeffrey J. Seilhamer, Lynn E. Murry
-
Patent number: 6060250Abstract: The invention provides three human transferases (HUTRAN) and polynucleotides which identify and encode HUTRAN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of HUTRAN.Type: GrantFiled: June 30, 1998Date of Patent: May 9, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Olga Bandman, Jennifer L. Hillman, Karl J. Guegler, Gina A. Gorgone, Neil C. Corley, Chandra Patterson
-
Patent number: 6057110Abstract: The present invention provides a polynucleotide (hhp) which identifies and encodes a novel human hyaluronidase (HHP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HHP. The invention also provides for the use of substantially purified HHP and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of HHP. Additionally, the invention provides for the use of antisense molecules to hhp in pharmaceutical compositions for treatment of diseases associated with the expression of HHP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of hhp. The present invention also relates to anti-HHP antibodies which specifically bind to HHP.Type: GrantFiled: December 17, 1998Date of Patent: May 2, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Janice Au-Young, Phillip R. Hawkins, Jennifer L. Hillman
-
Patent number: 6057140Abstract: The invention provides human SCAD family molecules (HSFM) and polynucleotides which identify and encode HSFM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSFM.Type: GrantFiled: June 30, 1998Date of Patent: May 2, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Karl J. Guegler, Gina A. Gorgone, Neil C. Corley, Mariah R. Baughn, Henry Yue
-
Patent number: 6057108Abstract: The invention provides human ARF-related proteins (HARP) and polynucleotides which identify and encode HARP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HARP.Type: GrantFiled: June 23, 1998Date of Patent: May 2, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Olga Bandman, Karl J. Guegler, Neil C. Corley, Henry Yue, Chandra Patterson
-
Patent number: 6054290Abstract: The present invention provides a human vesicle binding protein (MVBP) and polynucleotides which identify and encode MVBP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing MVBP and for treating or preventing disorders associated with expression of MVBP.Type: GrantFiled: May 15, 1997Date of Patent: April 25, 2000Assignee: Incyte Pharamaceuticals, Inc.Inventors: Olga Bandman, Phillip R. Hawkins, Lynn E. Murry
-
Patent number: 6054292Abstract: The invention provides a human T-cell receptor protein (TCRLP) and polynucleotides which identify and encode TCRLP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of TCRLP.Type: GrantFiled: July 18, 1997Date of Patent: April 25, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Neil C. Corley
-
Patent number: 6051692Abstract: The present invention provides a human retinoid binding protein (Hu-RBP) and polynucleotides which identify and encode Hu-RBP. The invention also provides expression vectors, host cells, antibodies and antagonists. The invention also provides methods for the prevention and treatment of diseases associated with expression of Hu-RBP, as well as diagnostic assays.Type: GrantFiled: January 22, 1999Date of Patent: April 18, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Preeti Lal, Joanne R. Petithory
-
Patent number: 6051697Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel chemokine (EEC) expressed in human eosinophil cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode EEC, expression vectors for the production of purified EEC, antibodies capable of binding specifically to EEC, hybridization probes or oligonucleotides for the detection of EEC-encoding nucleotide sequences, genetically engineered host cells for the expression of EEC, diagnostic tests for chemokine activation based on EEC-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.Type: GrantFiled: July 10, 1998Date of Patent: April 18, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Roger Coleman, Susan G. Stuart
-
Patent number: 6048718Abstract: The present invention provides a human mitochondrial F6 subunit (HMF6) and polynucleotides which encode HMF6. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for treating disorders associated with expression of HMF6.Type: GrantFiled: December 4, 1998Date of Patent: April 11, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Purvi Shah
-
Patent number: 6048970Abstract: The invention provides two human prostate growth-associated membrane proteins (PGAMP) and polynucleotides which identify and encode PGAMP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of PGAMP.Type: GrantFiled: May 22, 1998Date of Patent: April 11, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Karl J. Guegler, Neil C. Corley
-
Patent number: 6046001Abstract: The invention provides human fatty acid beta-oxidation enzymes (HUFA) and polynucleotides which identify and encode HUFA. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HUFA.Type: GrantFiled: December 31, 1997Date of Patent: April 4, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Jennifer L. Hillman, Karl J. Guegler, Neil C. Corley, Y. Tom Tang, Purvi Shah
-
Patent number: 6046029Abstract: The invention provides a human fatty acid synthase-like protein (HFASLP) and polynucleotides which identify and encode HFASLP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HFASLP.Type: GrantFiled: November 24, 1997Date of Patent: April 4, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Henry Yue, Neil C. Corley
-
Patent number: 6046027Abstract: The invention provides a human retinoid binding protein (RBPhu) and polynucleotides which identify and encode RBPhu. The invention also provides expression vectors, host cells, agonists, antibodies antagonists. The invention also provides methods for treating disorders associated with expression of RBPhu.Type: GrantFiled: July 22, 1997Date of Patent: April 4, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Karl J. Guegler, Purvi Shah
-
Patent number: 6045792Abstract: The present invention provides novel human protein kinases (HPK) and polynucleotides which identify and encode HPK. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPK. The invention also provides for pharmaceutical compositions comprising HPK or antagonists of HPK, and antibodies which specifically bind HPK. Additionally, the invention provides antisense molecules to HPK for treatment or prevention of diseases associated with abnormal expression of HPK.Type: GrantFiled: July 7, 1998Date of Patent: April 4, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Janice Au-Young, Karl J. Guegler, Phillip R. Hawkins
-
Patent number: 6046315Abstract: The invention provides a human disease associated calmodulin protein (DACP-1) and polynucleotides which identify and encode DACP-1. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of DACP-1.Type: GrantFiled: November 3, 1997Date of Patent: April 4, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer Hillman, Purvi Shah, Neil C. Corley
-
Patent number: 6043056Abstract: The invention provides human cell surface glycoproteins (CSGP) and polynucleotides which identify and encode CSGP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of CSGP.Type: GrantFiled: November 6, 1998Date of Patent: March 28, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Henry Yue, Neil C. Corley, Karl J. Guegler, Gina A. Gorgone, Mariah R. Baughn
-
Patent number: 6043222Abstract: The invention provides a two new human DnaJ-like proteins (HSPJ1 or HSPJ2) and polynucleotides which identify and encode HSPJ1 or HSPJ2. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of HSPJ1 or HSPJ2.Type: GrantFiled: September 2, 1999Date of Patent: March 28, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Janice Au-Young, Preeti Lal, Olga Bandman
-
Patent number: 6043343Abstract: The present invention provides novel human tumor proteins (collectively called TUPRO) and polynucleotides which identify and encode TUPRO. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding TUPRO. The invention also provides pharmaceutical compositions containing TUPRO or antagonists to TUPRO, and in the use of these compositions for the treatment of diseases associated with the expression of TUPRO. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding TUPRO for the treatment of diseases associated with the expression of TUPRO. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, to hybridize to the genomic sequence or transcripts of polynucleotides encoding TUPRO or anti-TUPRO antibodies which specifically bind to TUPRO.Type: GrantFiled: September 29, 1998Date of Patent: March 28, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Janice Au-Young, Surya K. Goli, Jennifer L. Hillman